Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved.
Researched for
Liver-fat reduction in non-alcoholic fatty liver disease (NAFLD/MASLD)Weight reduction in obesityMetabolic parameters in type 2 diabetes
Official status
US: Unapproved
No FDA approval. Investigational compound in clinical development (Merck); the FDA granted Fast Track designation for the NASH indication. Availability only within clinical trials.
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · single evidence tier
Human RCT
4
03
What the studies show
Human RCT
Mensch
Romero-Gómez M. et al. 2023
Greater relative reduction in liver fat content than semaglutide reported in a 24-week phase-2a trial
What does NOT follow: Open-label phase-2a study with active comparator, n=145, imaging surrogate endpoint (liver fat via MRI-PDFF); histological and clinical long-term endpoints pending. Not a usage recommendation.
Human RCT
Mensch
Alba M. et al. 2021
Dose-dependent weight reduction documented in individuals with obesity without type 2 diabetes over 26 weeks
What does NOT follow: Phase-2 dose-ranging with placebo and active comparator (liraglutide); increased rate of gastrointestinal events. No phase-3 data available.
Human RCT
Mensch
Di Prospero NA. et al. 2021
In type 2 diabetes, weight reduction was observed but no improvement in HbA1c versus placebo
What does NOT follow: Phase-2 dose-ranging; the lack of HbA1c lowering and increases in fasting glucose and insulin are linked to the glucagon component. No assessment of clinical benefit.
Human RCT
Mensch
Alba M. et al. 2021
Gastrointestinal events (nausea, vomiting) occurred dose-dependently and more frequently than under the comparator substances
What does NOT follow: Profile similar to other incretin-based substances but in part more pronounced; titration phase relevant. Observation from phase-2 studies.
04
Where studies disagree
Open question
Does the greater liver-fat reduction versus semaglutide translate into a relevant clinical benefit in MASH?
POSITION A
The phase-2a study showed a significantly greater relative reduction in liver fat (imaging surrogate endpoint) than semaglutide.
POSITION B
Liver fat is a surrogate endpoint; histological improvement, fibrosis endpoints and clinical outcomes were not demonstrated, and gastrointestinal events were more frequent.
CURRENT STATE · Open. No phase-3 data with hard endpoints are available; the assessment remains preliminary.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 115 h. Pure pharmacokinetic model — not a dosing recommendation.
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
There is no approved human use for this substance. What circulates online about amounts and frequency is self-experimentation without a safety net.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Typical of incretin agonists; somewhat more frequent than semaglutide in the phase 2 trial.
häufig
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
Efinopegdutide (MK-6024) is discussed as a potent GLP-1/glucagon dual agonist, especially for liver fat (MASH/NAFLD) and weight loss.
growing interest since the NAFLD phase 2 data
Not supported by studies: Investigational (phase 2), not approved; long-term and clinical outcome data are lacking.
11
Legal status by country
Country
Status
Note
Checked
United States
Unapproved
No FDA approval. Investigational compound in clinical development (Merck); the FDA granted Fast Track designation for the NASH indication. Availability only within clinical trials.
2026-06-07
Germany
Unapproved
No EMA approval. Investigational compound; availability only within clinical trials.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study